A New Initiative to Boost Advanced Therapy Medicinal Products Development
The University of Sheffield in concert with pharmaceutical giant Pfizer, has announced the creation of a new consortium to help accelerate the development of Advanced Therapy Medicinal Products (AMTPs), enabling radical new treatments such as gene therapy to reach patients sooner.
The Accelerating Research and Innovation for Advanced Therapies (ARDAT) consortium will bring together 34 academic, nonprofit and private organisations from across Europe and the United States. They will bring their expertise to bear on a €25.5 million project to accelerate ATMP development.
Rapid growth is expected in the AMTP field, with the submission of some 10-20 new drug applications annually to the FDA by 2025.
“While still an emerging field, ATMP research has largely been fragmented and siloed within organisations with little opportunity to share best practices and information,” said Dr Greg LaRosa, Head of Scientific Research, Rare Disease Research Unit at Pfizer.
“As gene and cell therapies research grows and more potential ATMPs move into later-stage clinical trials, it is in the interest of the industry and of patients to further our collective understanding of their mechanisms by sharing data and regulatory expertise.”
Source: University of Sheffield
